Fresh analysis suggests that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who halt traditional diet and exercise plans.
Published data in a major medical journal shows that while overweight people can lose about a fifth of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Users buying such drugs must be aware of the danger of quick weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
This pace of regain suggests a return to original mass in about a year and a half.
Weighing Approaches
The research, which examined 37 of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
Scientists point out that individuals who shed pounds through diet and exercise generally experience a more gradual creep back—around 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Doctors propose the mechanism of the jabs accounts for the amplified regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels far above than the body's typical production might result in the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication means hunger is unsuppressed, making binge eating much more probable."
An Ongoing Disease?
The NHS suggest the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, due to the likelihood of weight regain, the treatment should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who state that the results "emphasize the long-term nature of obesity," akin to managing diseases like hypertension.
User Testimonies
People who have stopped the jabs explain a intense return of cravings.
"It was like a trigger flipping and you become starving," described an individual.
This difficulty is compounded if patients have not adopted sustainable dietary or behavioural modifications during therapy.
Widespread Interest
Figures indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while these medications are potent tools for shedding pounds, they are not a permanent fix and long-term success hinges on integrated behavioural management.
